Blogs Detail
Views: 149 Author: Site Editor Publish Time: 2026-06-29 Origin: Site
The global market for hyaluronic acid based dermal fillers is valued at approximately $6.7 billion in 2025 and is projected to grow at a CAGR of 12.4% to reach almost $19.2 billion by 2034. This is an incredible opportunity for an international filler distributor – if you can navigate the complex regulatory landscape for importing and selling dermal fillers, particularly in the European market.
CE certification is at the heart of this regulatory regime. Understanding the CE certification process for dermal fillers is not just a question of compliance for distributors, clinic owners and brand developers, it is a competitive advantage that has a direct impact on your ability to source, stock and sell these products with confidence.
The CE mark is used by manufacturers to show that their products meet all the essential requirements of the relevant European health, safety and environmental protection legislation. This certification for dermal fillers is under the Medical Devices Regulation (EU) 2017/745 (i.e. MDR), which became fully applicable in May 2021.
Under the MDR, dermal fillers are classified as medical devices – even when used only for cosmetic purposes such as wrinkle correction or lip augmentation. According to the EU Medical Devices Regulation, all dermal fillers placed on the EU market must carry the CE mark to show they fulfil strict safety and performance requirements.
For distributors and brand owners, this means a critical reality: If your dermal filler products are not CE marked, they cannot be placed on the market in Europe.
The CE certification process for dermal fillers is a multi-stage process, requiring significant investment in quality systems, clinical evidence and regulatory expertise. The procedure is as follows:
Dermal fillers are listed in Annex XVI of the MDR. This annex concerns products which are not intended to have a medical purpose, but which behave like medical devices and pose similar risks. Classification is by product characteristics:
● Absorbable dermal fillers are generally considered Class III—highest risk.
● Products containing medicinal substances (e.g. lidocaine) are considered to be combination products in accordance with Article 1(8) of the MDR.
Class III devices require the most rigorous conformity assessment, including mandatory clinical studies that are designed and scoped similar to Phase III pharmaceutical trials.
Manufacturers of Class III dermal fillers have to work with an independent Notified Body, a conformity assessment body designated by the authorities of the European Union. The Notified Body reviews the manufacturer’s technical documentation, quality management system and clinical evidence before issuing CE certification.
Manufacturers need to generate robust clinical data proving safety and performance of their dermal fillers.” This normally involves:
● Preclinical testing (biocompatibility, sterilisation validation, shelf life studies)
● Clinical studies in humans
● Clinical follow-up studies after market introduction (PMCF)
Manufacturers must implement and maintain a certified quality management system—typically ISO 13485—covering all stages from design control to production and post-market surveillance.
Once the notified body has confirmed compliance, the manufacturer draws up an EU Declaration of Conformity and affixes the CE mark to the product. The product is then registered in the European Database on Medical Devices (EUDAMED) and assigned a Unique Device Identification (UDI).
For you as an international filler distributor, your regulatory obligations go beyond just selecting products with CE certification. Under the MDR, Distributors shall:
Check CE marking on products and that relevant technical documentation and instructions for use are available
● Ensure the labelling complies with the language requirements of the target country
● Maintain records of traceability and demonstrate due diligence to competent authorities
● Storage and transport conditions shall not affect the compliance of the product
The stakes are higher for brand owners eyeing private label or OEM deals. You should verify that your manufacturing partners have CE certification and the quality systems and regulatory infrastructure to support ongoing compliance.
Not all CE certifications are the same. The old Medical Device Directive (MDD) has now been replaced by the new Medical Device Regulation (MDR) which has far stricter requirements. Products certified under the old system will have to transition to the MDR certification before December 31, 2027 or 2028 (depending on risk classification).
Here are some of the main things to look for when evaluating potential suppliers:
● Valid MDR CE certificate (not MDD certificate)
● ISO 13485 QMS certification
● GMP manufacturing (Class 100 or better)
● Clinical evidence to support safety and performance claims
● Clear regulatory documentation available on demand
For over 23 years, AOMA CO., LTD. has been the trusted partner for international filler distributors, aesthetic clinics and brand owners. We export our products to more than 120 countries including the European Union, United States and major markets in Latin America, Middle East and Asia.
All AOMA dermal fillers are manufactured with full respect to CE and FDA regulatory standards and certified to ISO 13485 quality management system. We are proud to be CE certified dermal filler products, meeting the stringent requirements of the EU Medical Devices Regulation – giving you and your clients confidence in each injection.
We are committed to filler regulatory compliance throughout the entire production process, from raw material screening to aseptic manufacturing to finished product testing.
Our factory occupies an area of 4800 square meters, equipped with a first-class Class 100 GMP pharmaceutical production workshop, the highest standard in the industry. The facility has three production lines with a daily capacity of 500,000 units of sodium hyaluronate gel. It uses advanced equipment, such as Germany’s INOVA high-viscosity pre-filled syringe filling machines and Sweden’s GETINGE constant-pressure moist-heat sterilisers, to ensure consistency and quality in large-scale production.
AOMA is one of the top 10 manufacturers of hyaluronic acid fillers in China and has successfully customised products for over 580 brands, with a customer satisfaction rate of 99.5%. Our ISO-certified Filler factory operates to six-sigma quality standards. We spend more than 10% of our annual turnover on R&D.
We are professional HA fillers exporters, providing all-in-one OEM/ODM services with only 2-3 weeks production lead time. We have more than 1,000 proven formulations and offer flexible customisation of branding, packaging, formulas and volumes to help you build your own brand while maintaining quality and regulatory compliance.
Any distributor who wants to grow into the European market needs to understand filler import regulations. Major requirements include:
● The CE mark must be easily visible on the product and the product packaging.
● Instructions for use must be in the official language(s) of the target country.
● Products need a UDI and registration in EUDAMED.
● A post-market surveillance system shall be established to monitor product performance and report adverse events.
AOMA offers strong regulatory support to our distribution partners through technical documentation, certificates and compliance guidance to ensure smooth market access.
In 2024, a distributor in Eastern Europe – a mid-sized network of aesthetic clinics – contacted us, looking for a reliable supplier of CE-certified dermal fillers. Previously, they had struggled with inconsistent product quality and lack of regulatory paperwork from their current manufacturer, which put their business at risk.
They placed their first order for HA fillers after reviewing our CE certification, ISO 13485 accreditation and GMP manufacturing standards. They reported a 35% increase in patient satisfaction and a 28% decrease in product-related complaints at 6 months. “The high batch-to-batch consistency of our fillers has led to significantly better treatment results and patient confidence,” said the clinic’s medical director.
Today, they are our sole distributor for the region and we are working on creating a private label product line for their growing network of clinics.
It’s not a luxury, it’s a must-have for international filler distributors, brand owners and clinic operators who want to enter the European market and win the trust of demanding customers. “Improperly certified products expose you to regulatory penalties, damage to reputation and more importantly, risks to patient safety.
Sustainable growth in the most attractive medical aesthetics market in the world can be achieved by partnering with manufacturers who are CE certified for dermal fillers, have ISO certified production facilities and are compliant with filler regulatory compliance standards.
Related News
Laboratory
Product Category
Blogs